MedTrace Logo

Effect of Astaxanthin on the Patients With Alzheimer Disease

NCT05015374 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-09-27

No results posted yet for this study

Summary

This study adapts a randomized, double-blind, placebo-controlled trial, to exam the possible benefit of Astaxanthin on Alzheimer disease. The enrolled Alzheimer patients will take Astaxanthin or placebo for 1 year. We will follow up Mini-Mental State Examination, Cognitive Ability Screening Instrument, Clinical Dementia Rating, and Neuropsychiatric Inventory at the end of the study.

Conditions

  • To Evaluate the Possible Benefit of Astaxanthin on Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Astaxanthin

350 mg/capsule (2mg Astaxanthin)

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • China Medical University, China

    collaborator OTHER

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-14
Primary Completion
2024-06-01
Completion
2024-06-25

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05015374 on ClinicalTrials.gov